000			03023nam a22003137a 4500
999			_c9085 _d9085
003			PILC
005			20240720152743.0
008			160505b2013 xxu||||| |||| 00| 0 eng d
040			_cFEU-NRMF MEDICAL LIBRARY
050			_aMT 2013 0002
100			_aAlicia A. Aldave, RMT _eadviser
111			_dSeptember 2013
245			_aCommercial Bromelain as an Anticoagulant / _cAndre Vinzon I. Baldovino ; Mark Jeffrey C. Merced ; Audilyn P. Montano ; Venice Vernadette SJ. Nicolas ; Rommel Banjo Q. Pangan and Pia Karla S. Tempongko.
260			_aFairview, Quezon City _bSchool of Medical Technology, FEU-NRMF _cSeptember 2013
300			_a28 pages: _billustrations, tables, photos; _c28 cm.
336			_2rdacontent _atext
337			_2rdamedia _aunmediated
338			_2rdacarrier _avolume
504			_aIncludes appendices and bibliographical references.
520			_aAbstract: The goal of the study is to prove that bromelain has an anticoagulant property in vitro. Bromelain is an enzyme coming from the pineapple proven by other studies to have an anticoagulant effect. It possesses anticoagulant properties in vivo which reduce the ability of platelets to clump together, or aggregate, reports a paper published in the January-February 1999 issue of the medical journal "in Vivo" In the attempt to give a broader source of anticoagulant, the researchers thought of utilizing the commercialized pure and natural bromelain powder. The researchers determined the blood to anticoagulant ratio by means of trial and error method, using EDTA as the positive and whole blood as negative control. Bromelain powder was diluted to varying volumes of NSS to attain different anticoagulant concentrations. They determined the length of time of the anticoagulant activity of the bromelain by recording the time on which no clotting occurs after examining the presence and absence of clot formation. Then morphology was tested with the use of Wright and Giemsa staining technique. After subjecting specimens of blood to series of bromelain concentration the results showed anticoagulant activities that lasted from more than 24 minutes to less than 6 hours, but denied of positive findings due to use of EDTA as positive control. Also, the results showed that blood cells with bromelain powder were morphologically similar as that of blood cells using EDTA. Therefore the researchers concluded that the commercially prepared bromelain has an anticoagulant property. It had a longer anticoagulant activity than the negative control and no morphologic changes were noted in blood smear with bromelain as compared with EDTA. The blood cells with bromelain have the same appearance as that of EDTA.
521			_aTHMT
700			_aBaldovino, Andre Vinzon _eauthor
700			_aMerced, Mark Jeffrey C. _eauthor
700			_aMontano, Audilyn P. _eauthor
700			_aNicolas, Venice Vernadette SJ. _eauthor
700			_aPangan, Rommel Banjo Q. _eauthor
700			_aTempongko, Pia Karla S. _eauthor
942			_2lcc _cTH